Now that it has plenty of extra expertise and manufacturing capacity to make biologic drugs thanks to the addition of Wyeth, Pfizer
Welcome to the club. It's getting crowded in here. Teva Pharmaceutical
I understand Pfizer's need to move away from a reliance on a single blockbuster like Lipitor; diversified lineups like those of Johnson & Johnson and Abbott Labs have served them well. But investors should realize that the development of biologics is going to take time.
At this point, Pfizer is playing catch-up. Sure, the U.S. doesn't currently have a pathway to approve so-called follow-on biologics, but it most likely will in the not-too-distant future; the health-care reform bill is expected to contain instructions for the Food and Drug Administration to set one up. It'll likely take years to develop the products from scratch, and Pfizer might be best off getting a jump-start by purchasing or licensing follow-on biological drugs already in development -- as Mylan and Merck
One potential target could be Dr. Reddy's Laboratories
Besides, Pfizer, I hear now's the time to invest in India.
Pfizer is a Motley Fool Inside Value selection. If you're interested in picking through the wreckage for possible turnaround candidates, you should have the Inside Value team on your side. Check it out for free with a 30-day trial.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is an Income Investor recommendation. Novartis is a Global Gains selection. The Fool's disclosure policy is anything but generic.